Biogen Executive Kenneth DiPietro Joins InVivo Therapeutics Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that Kenneth DiPietro, Executive Vice President Human Resources at Biogen Idec, has joined InVivos Board of Directors. DiPietro has also been appointed as Chair of the Boards Governance, Nominating and Compensation committee.

InVivo has pioneered a new technology platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic spinal cord injury. Today there is no effective treatment for traumatic spinal cord injuries, and the market potential is estimated to exceed $10 billion.

Mr. DiPietro brings 30 years of experience in the human resources field to InVivos Board. As a senior executive and respected global business leader, Mr. DiPietro is accomplished at linking human resources functional excellence to the achievement of corporate objectives. He has gained broad cultural transformation, organizational development and corporate re-engineering experience with several Global 500 companies including Biogen, Microsoft, and PepsiCo, Inc.

We expect that 2013 will be a breakout year for InVivo and that the next six months will mark a major inflection point in our growth," said Frank Reynolds, InVivos Chief Executive Officer. "We have built out strong R&D capabilities in neurotrauma and weve completed important manufacturing runs for our final submission to the FDA in early 2013. Were poised to move our SCI devices into clinical trials and are aggressively developing multiple neurotrauma products for pain, fibrosis, and dural sealing.

Continued Reynolds, In 2012, we raised over $23 million including $20 million in a public offering from blue chip institutional investors. Weve recruited a world-class team of experts in neuroscience and neurosurgery to fill our premier R&D center and our cGMP manufacturing facility. For 2013, well have a unique opportunity to scale InVivos biomaterials platform into products beyond spinal cord injury treatments, and solid human resource planning will be at the center of our strategy.

I am confident that Kens talents and abilities will add value to InVivo and our Board by helping the Company manage growth. Hell help InVivo implement a vision to enhance productivity, while promoting exceptional business performance by framing a human resources agenda and defining strategies. I am very pleased to be able to welcome him to the InVivo team.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement

See more here:
Biogen Executive Kenneth DiPietro Joins InVivo Therapeutics Board of Directors